tbuckley/cabot-search huggingface dataset:
TCT-547 Efficacy and safety of platinum-chromium everolimus-eluting stents compared with other second-generation drug-eluting stents. Meta-analysis from 5 randomized trials including 7,896 patients
Authors: Raul Moreno, Hyo-Soo Kim, Clemens von Birgelen, Gregg W. Stone, Seung-Jung Park, Jose M. De la Torre Hernandez, Katie Qureshi, Keith D. Dawkins
Journal: Journal of the American College of Cardiology (2015)
TCT-609 Malapposition, Strut Coverage, and following implantation of the Resolute Integrity Stent in patients with ST Segment elevation myocardial Infarction assessed by Optical Coherence Tomography
Authors: Mikkel Hougaard, Henrik S. Hansen, Per Thayssen, Akiko Maehara, Gary S. Mintz, Lisbeth Antonsen, Anders Junker, Knud N. Hansen, Karsten T. Veien, Knud Erik Pedersen, Lisette Okkels Jensen
Journal: Journal of the American College of Cardiology (2015)
A novel intra-thoracic hyperthermic schedule combining gemcitabine (Gem) and cisplatin (Pt) in patients with pleural mesothelioma: A pharmacokinetic analysis
Authors: G. A. Milano, T. Besnard, N. Renée, M. Etienne-Grimaldi, J. Mouroux, L. Brouchet, D. Pop, R. Garraffo, N. Venissac
Journal: Journal of Clinical Oncology (2008)

2551 Background: A multimodal approach based on debulking surgery is beneficial in the treatment of pleural mesothelioma (PM). In addition, hyperthermic intra-thoracic chemotherapy significantly improves patient survival. Chemotherapeutic agents such as gemcitabin (Gem) have proven their efficacy in PM. The aim of this study was to assess the feasibility, tolerability and pharmacokinetics (PK) of gemcitabine (Gem)-cisplatine (Pt) both administered using this new intra-thoracic hyperthermic schedule. Methods: A phase II study was conducted in patients with T<3, N<2, M0 epithelioid mesothelioma. After neoadjuvant chemotherapy (Gem-Pt), extra-pleural pneumonectomy with diaphragmatic and pericardic reconstruction was performed, followed by a 1-hour intra-thoracic hyperthermic infusion of Pt (100 mg/m²) + Gem (1250 mg/m²). Pleural and blood samples were analyzed for Gem and its active metabolite difluorodeoxyuridine (dFdU, HPLC assay) and for total and free Pt concentrations (atomic absorption spectrophotometry). Five patients were analyzed for PK. Results: No major chemotherapy-related side effect was reported. Main PK data are the following: the maximum dFdU concentration was reached between 1.25 and 1.5 h in pleura, and between 1.25 and 4 h in plasma. For free Pt, maximum concentrations were observed between 0.25 and 1 h in pleura and between 1 and 1.25 h in plasma. Large inter-patient variability was observed for both dFdU and free Pt PK. Importantly, the local exposure to dFdU was 2.5 to 9-fold that of plasma exposure. For free Pt, pleural exposure was 8.7 to 30-fold greater than plasma exposure. Conclusions: These data indicate a markedly higher pleural exposure as compared to systemic exposure for dFdU and Pt. Along with satisfactory tolerance, these results support the potential benefit offered by this new intra-thoracic hyperthermic schedule in the management of PM. Patient AUC0–48h dFdU (μM.h) AUC0–48h free Pt (mg/l.h) Plasma Pleura Pleura/plasma Plasma Pleura Pleura/plasma 1 913 2,350 2.57 6.96 60.65 8.71 2 304 1,396 4.59 5.44 not done - 3 379 953 2.51 1.87 56.68 30.31 4 537 4,856 9.04 4.26 100.87 23.68 5 386 1,453 3.76 1.82 29.72 16.29 No significant financial relationships to disclose.
Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans
Authors: Julie A. Poposki, Aiko I. Klingler, Whitney W. Stevens, Anju T. Peters, Kathryn E. Hulse, Leslie C. Grammer, Robert P. Schleimer, Kevin C. Welch, Stephanie S. Smith, Douglas M. Sidle, David B. Conley, Bruce K. Tan, Robert C. Kern, Atsushi Kato
Journal: Journal of Allergy and Clinical Immunology (2016)
Capecitabine monotherapy and the clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with metastatic colorectal cancer.
Authors: Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Sung Yong Oh, Ji Hyun Lee, Hyun-Hwa Yoon, Hong Jo Choi, Hyo-Jin Kim
Journal: Journal of Clinical Oncology (2012)

660 Background: Oxaliplatin- and irinotecan-based combination chemotherapy with infusional 5-FU and leucovorin are currently the standard therapies for metastatic colorectal cancer. The objectives of this study were to evaluate the efficacy of capecitabine monotherapy as third line therapy for metastatic colorectal cancer after failure of chemotherapy containing oxaliplatin and irinotecan, and to determine whether the neutrophil-lymphocyte ratio (NLR), or the platelet-lymphocyte ratio (PLR) are significant prognostic marker in metastatic colorectal cancer. Methods: We analyzed 60 patients with metastatic colorectal cancer who received capecitabine monotherapy after the failure of FOLFOX and FOLFIRI. Capecitabine was administered at 1250mg/m2 twice daily for 2 weeks, every 3 weeks. The NLR and PLR were calculated from complete blood counts in baseline laboratory test before the first cycle chemotherapy. Results: The overall response rate was 6.7% and stable disease was 41.7%. The disease control rate was 48.3%. The median progression-free survival (PFS) was 2.8 months (95% CI, 1.5-4.1 months) and the median overall survival (OS) was 9.7 months (95% CI, 7.6-11.7 months). The most frequent adverse event was hand-foot syndrome (all-grade 26.6%; grade3 5%). The response of capecitabine, NLR, and PLR were observed as good prognostic markers of OS in univariate analysis (p&lt;0.001, 0.004, and 0.002, respectively). The response of capecitabine and PLR were independent prognostic marker in multivariate analysis (Hazard ratio 2.757, 95% CI 1.357-5.599, p=0.005 and hazard ratio 2.091, 95% CI 1.231-3.552, p=0.006, respectively). Conclusions: The capecitabine monotherapy showed a moderate disease control and a tolerable toxicity profile as third line treatment for metastatic colorectal cancer. The response of capecitabine and PLR may be simple and useful prognostic index for metastatic colorectal cancer.
TCT-743 Safety and Effectiveness of Transcatheter Closure of Ostium Secundum Atrial Septal Defect Using Atrial Septal Occluder Device Without Balloon Sizing or Invasive Echocardiogram in Low Health Resource Setting
Authors: Uditha I. Hewarathna, Naradha W. Kodithuwakku, Shanike P. Karunaratne, Hgwapl Bandara, Thangarajah Kogulan, Gnanamoorthy Mayurathan, Gamini Weerakoon, Ajith I. Kularatne, Dinesha T. Ambagaspitiya
Journal: Journal of the American College of Cardiology (2015)
Untreated Hypertension
Authors: Kyle B. Walsh, Daniel Woo, Padmini Sekar, Jennifer Osborne, Charles J. Moomaw, Carl D. Langefeld, Opeolu Adeoye
Journal: Circulation (2016)

Background: Hypertension is a significant risk factor for intracerebral hemorrhage (ICH). Although ethnic/racial disparities related to hypertension and ICH have been reported, these previous studies were limited by a lack of Hispanics and inadequate power to analyze by ICH location. In the current study, while overcoming these prior limitations, we investigated whether there was variation by ethnicity/race of treated and untreated hypertension as risk factors for ICH. Methods: The ERICH study (Ethnic/Racial Variations of Intracerebral Hemorrhage) is a prospective, multicenter, case-control study of ICH among whites, blacks, and Hispanics. Cases were enrolled from 42 recruitment sites. Controls matched to cases 1:1 by age (±5 years), sex, ethnicity/race, and metropolitan area were identified by random-digit dialing. Subjects were interviewed to determine history of hypertension and use of antihypertensive medications. Cases and controls within ethnic groups were compared by using conditional logistic regression. Multivariable conditional logistic regression models were computed for ICH as an overall group and separately for the location subcategories deep, lobar, and infratentorial (brainstem/cerebellar). Results: Nine hundred fifty-eight white, 880 black, and 766 Hispanic ICH patients were enrolled. For ICH cases, untreated hypertension was higher in blacks (43.6%, P &lt;0.0001) and Hispanics (46.9%, P &lt;0.0001) versus whites (32.7%). In multivariable analyses adjusted for alcohol use, anticoagulation, hypercholesterolemia, education, and medical insurance status, treated hypertension was a significant risk factor across all locations of ICH in whites (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.24–1.98; P &lt;0.0001), blacks (OR, 3.02; 95% CI, 2.16–4.22; P &lt;0.0001), and Hispanics (OR, 2.50; 95% CI, 1.73–3.62; P &lt;0.0001). Untreated hypertension was a substantially greater risk factor for all 3 racial/ethnic groups across all locations of ICH: whites (OR, 8.79; 95% CI, 5.66–13.66; P &lt;0.0001), blacks (OR, 12.46; 95% CI, 8.08–19.20; P &lt;0.0001), and Hispanics (OR, 10.95; 95% CI, 6.58–18.23; P &lt;0.0001). There was an interaction between race/ethnicity and ICH risk ( P &lt;0.0001). Conclusions: Untreated hypertension confers a greater ICH risk in blacks and Hispanics relative to whites across all anatomic locations of ICH. Accelerated research efforts are needed to improve overall hypertension treatment rates and to monitor the impact of such efforts on racial/ethnic disparities in stroke. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01202864.
Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PM-Rara, CBFB-MYH11, and RUNX1-RUNX1T1: A Study on 600 Patients
Authors: Torsten Haferlach, Manja Meggendorfer, Susanne Schnittger, Annette Fasan, Wolfgang Kern, Claudia Haferlach
Journal: Blood (2015)
TCT-658 Left Bundle Branch Block and Need for Permanent Pacemaker Post TAVR
Authors: Grace M. Wu, Abdulla Damluji, Yahya E. Alansari, Mohamad Kabach, Magdalena Murman, Italo C. Novoa, Christopher Healy, Roger Carillo, Donald Williams, Eduardo de Marchena, Claudia A. Martinez, Carlos Alfonso, Mauro Moscucci, Alan W. Heldman, Mauricio G. Cohen, Raul Mitrani, Lionel Leroux
Journal: Journal of the American College of Cardiology (2015)
Oligometastatic prostate cancer: An evaluation of stereotactic body radiotherapy (SBRT) as an alternative to palliative androgen deprivation therapy.
Authors: Daniel Robert Henderson, Alison Tree, Helen Taylor, Vincent Khoo, Nicholas John Van As
Journal: Journal of Clinical Oncology (2015)

229 Background: Oligometastatic prostate cancer (OPC) can be defined as 1-3 sites of metastasis, typically occurring some years after radical treatment for primary disease. Standard treatment is long-term palliative androgen deprivation therapy (ADT). Although effective, this treatment can have a significant impact on quality of life. We hypothesized that ablative treatment with SBRT may delay disease progression, and therefore the need for palliative ADT. Methods: A single-institution case series 2011-present. Eligible patients had metachronous OPC diagnosed by F-choline PET/CT and were ADT-naïve in the palliative setting. Stereotactic body radiotherapy was given to a dose of 30 Gy in 3 fractions using a robotic radiosurgery system (Cyberknife). ADT-free survival was calculated as the time from completion of treatment for oligometastatic disease to initiation of ADT with palliative intent. Follow up with clinical review and PSA was undertaken at four weeks, then three monthly, with F-choline PET/CT restaging as indicated. Palliative ADT was initiated for metastatic disease not amenable to further SBRT. Results: Twenty one patients received SBRT for ADT-naïve OPC. Median time from primary treatment to oligometastatic relapse was 59.7 months. Median PSA doubling time was 4.1 months. Six patients received a short course (3-6 months) of ADT with SBRT. Sites treated: bone (8) and lymph node (20). At a median follow up of 16.7 months, 81% (17) remained ADT-free. Median ADT-free survival was 28 months (95% CI: 10 - 43 months). All but one patient had a PSA response, with a median reduction of 84%. There were no local failures. Incidence of grade 1 and 2 CTCAE toxicity was 29% (6) and 5% (1), respectively. No toxicity of grade 3 or above was observed. Conclusions: SBRT for OPC is well tolerated. A clinically significant delay in initiation of palliative ADT was observed in patients with ADT-naïve oligometastatic disease. In view of this potential to improve patients’ quality of life, randomised trials against a standard of care are justified.
A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)
Authors: R. Srinivasan, T. K. Choueiri, U. Vaishampayan, J. E. Rosenberg, M. N. Stein, T. Logan, R. M. Bukowski, T. Mueller, H. N. Keer, W. M. Linehan
Journal: Journal of Clinical Oncology (2008)

5103 Background: XL880 is a potent, orally available small molecule inhibitor of MET and VEGFR2/KDR. Activating mutations and/or amplifications in MET have been described in pts with PRC. In a XL880 Phase 1 study with intermittent dosing, 3 of 4 PRC pts had partial responses (PR), two of which are durable for >2 and 1 year respectively. Methods: This is a phase II study enrolling PRC pts stratified based on presence or absence of MET-pathway dysfunction (activating mutation in MET kinase domain, MET [7q31] amplification, or trisomy 7). Pts with PRC, adequate organ function and ECOG 0–2, receive XL880 at 240 mg/day on Days 1–5 of 14 day treatment cycles. Response is assessed every 8 weeks by RECIST criteria. Plasma markers reflecting effects of anti-angiogenic therapy and potential effects of MET inhibition are analyzed. Results: As of 21 Dec 2007, 26 subjects were enrolled (17 germ line MET wildtype, 4 hereditary PRC [HPRC] with a germ line MET mutation, 5 with MET pathway dysfunction). Of 20 evaluable pts, all had at least stable disease (SD), 17 had decreases in tumor size (range 1–35%) and for pts with adequate follow up, 12/18 and 10/17 had disease control (SD or PR) at >8 and >10 mos, respectively. Two pts have confirmed PRs and a third has PR pending confirmation. Five pts are too early to evaluate and one subject (following prior sunitinib treatment) developed hypertension and was removed from study. The most frequent adverse events (AEs) associated with XL880 were fatigue, hypertension, nausea, anorexia, and vomiting, primarily grades 1 and 2. In the majority of pts analyzed, administration of XL880 resulted in statistically significant changes in plasma levels of PlGF, VEGF-A, sVEGFR2, EPO, and sMET: effects suggestive of pharmacodynamic inhibition of VEGF and MET signaling by XL880. Conclusions: XL880 demonstrated antitumor activity in pts with PRC: 3 subjects with PR, all subjects having their first efficacy evaluation with at least stable disease, and all 3 HPRC patients with at least one restaging demonstrate ongoing tumor shrinkage (2 PR). XL880 was generally well tolerated in this pt population. PlGF, VEGF-A, sVEGFR2, EPO, and sMET are promising pharmacodynamic markers to monitor the biological activity of XL880. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Exelixis Exelixis
TCT-719 Paravalvular Prosthetic Regurgitation: Clinical Outcomes In Patients Undergoing Percutaneous Leak Closure And Surgical Repair
Authors: Freddy A. Brito Moscoso, Carlos P. Pinheiro, Eduardo Paiva Costa, Daniele Rezek, Edvagner S. Leite de Carvalho, Alexandre Abizaid, Amanda Sousa
Journal: Journal of the American College of Cardiology (2015)
cGAS-Mediated Innate Immunity Spreads Intercellularly through HIV-1 Env-Induced Membrane Fusion Sites
Authors: Shuting Xu, Aurélie Ducroux, Aparna Ponnurangam, Gabrielle Vieyres, Sergej Franz, Mathias Müsken, Thomas Zillinger, Angelina Malassa, Ellen Ewald, Veit Hornung, Winfried Barchet, Susanne Häussler, Thomas Pietschmann, Christine Goffinet
Journal: Cell Host & Microbe (2016)
Connective Tissue Growth Factor (Ctgf/Ccn2) Is a Novel Extrinsic Niche-Derived Regulator Of Hematopoietic Stem Cells
Authors: Baiba Vilne, Rouzanna Istvanffy, Christina Eckl, Franziska Bock, Sandra Grziwok, Prazeras da Costa Olivia, Matthias Schiemann, Christian Peschel, H. Werner Mewes, Robert A.J. Oostendorp
Journal: Blood (2013)
GW27-e0850 Clinical Characteristics and Treatments of Brugada Syndrome: A Retrospective Study in Chinese Population
Authors: Boshui Huang, Juan Meng, Ying Chen, Guiyi Yuan, Fasheng Liang, Huayuan Zeng, Juan Lei, Chang Fang, Shaoxin Zheng, Shuxian Zhou
Journal: Journal of the American College of Cardiology (2016)
Higher CD 34 Cell Doses Reduce Non Relapse Mortality (NRM) and Do Not Increase the Incidence of Graft Versus Host Disease (GVHD) Following Unrelated Donor Blood Stem Cell Transplantation (SCT).
Authors: Sujaatha Narayanan, Michael J. Barnett, Yasser R. Abou Mourad, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Kevin W. Song, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith, Maryse Power, Thomas J. Nevill
Journal: Blood (2007)
Sequential Kinase Inhibitor Therapy in CML Patients Can Select for Cells Harboring Compound BCR-ABL Kinase Domain Mutations with Increased Oncogenic Potency: Rationale for Early Combination Therapy of ABL Kinase Inhibitors.
Authors: Neil P. Shah, Brian Skaggs, Susan Branford, Timothy P. Hughes, John M. Nicoll, Ronald L. Paquette, Charles L. Sawyers
Journal: Blood (2006)
TCT-341 Thrombus And Plaque Erosion In Patients With Vasospastic Angina Using Optical Coherence Tomography
Authors: Eun-Seok Shin, Soe Hee Ann, Gillian K. Balbir Singh, Ae-Young Her, Eun Bo Shim, Bon-Kwon Koo, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2015)
HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients with Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT-LWP).
Authors: Rafael Duarte, Carme Canals, Francesco Onida, Eduardo Olavarria, William Arcese, Augustin Ferrant, Franco Narni, Andrea Bacigalupo, Donald Bunjes, Jacob Rowe, Giorgio Lambertenghi, Norbert Schmitz, Anna Sureda
Journal: Blood (2008)
TCT-7 Trends and outcomes of percutaneous coronary intervention for ventricular tachycardia or fibrillation cardiac arrest: analysis from nationwide inpatient sample
Authors: Nish Patel, Nileshkumar J. Patel, Pablo A. Rengifo-Moreno, Vikas Singh, Carlos Alfonso, Deepak L. Bhatt, Mauricio G. Cohen
Journal: Journal of the American College of Cardiology (2015)
GW27-e0215 The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride and periodontal markers in type 2 diabetic patients with chronic periodontitis
Authors: Ahmad Zare Javid, Razie Hormoznejad, Hojat allah Yousefimanes, Mehrnoosh Zakerkish, Mohammad Hosein Haghighi, Maryam Ravanbakhsh
Journal: Journal of the American College of Cardiology (2016)
Surveillance for Cancer Incidence and Mortality — United States, 2013
Authors: Simple D. Singh, S. Jane Henley, A. Blythe Ryerson
Journal: MMWR Surveillance Summaries (2017)

This report provides, in tabular and graphic form, official federal statistics on cancer incidence and mortality for 2013 and trends for 1999-2013 as reported by CDC and the National Cancer Institute (NCI). Data in this report come from the United States Cancer Statistics (USCS) system (1), which includes cancer incidence data from population-based cancer registries that participate in CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results (SEER) program reported as of November 2015 and cancer mortality data from death certificate information reported to state vital statistics offices as of June 2015 and compiled into a national file for the entire United States by CDC's National Center for Health Statistics (NCHS) National Vital Statistics System (NVSS).
Feasibility and preliminary efficacy of R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL)
Authors: J. L. Halaas, C. H. Moskowitz, A. Noy, C. Portlock, S. Horwitz, D. Straus, O. O'Connor, J. Yahalom, A. D. Zelenetz
Journal: Journal of Clinical Oncology (2004)

6584 Background: Standard first line therapy for DLBCL is CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Studies have shown that the addition of rituximab (R) or shortening the interval between cycles to two weeks improves survival. These studies prompted our institution, MSKCC, to treat newly diagnosed patients with DLBCL ineligible or refusing protocol-based therapy with R-CHOP-14. This retrospective review reports our experience with this regimen. Methods: We retrospectively identified patients with DLBCL without significant co-morbidities treated at MSKCC with R-CHOP-14. Patients received filgrastim and prophylactic sulfamethoxazole/trimethoprim, fluconazole and anti-herpes antibiotics. Erythropoietin was given per institutional guidelines. Patients received involved field radiation therapy to sites of early stage disease or bulky or symptomatic sites of disease and intrathecal prophylaxis if indicated. Results: In total, 49 patients were included for analysis. The median age was 52 (14/49 > 60); 20/49 with KPS ≤ 70%; 26/49 with elevated LDH; 18/49 ≥2 extranodal sites and 71% had advanced stage. According to the International Prognostic Index (IPI) 30.6% patients had low risk disease, 22.4% low-intermediate risk, 28.6% high-intermediate risk, and 18.4% high risk disease. Ninety-two percent of patients received 6 cycles of R-CHOP-14. Seventy-three percent of courses were delivered within 14 days and the planned dose was given in greater than 96% cycles for R, cyclophosphamide and doxorubicin but 67.5% for vincristine (VCR). Ten patients were hospitalized a total of 21 times; neutropenic fever occurred in 3.6% (9/252) of cycles given. Among evaluable patients 37/45 (82.2%) achieved a CR/CRu and 1 patient had refractory disease. Of 7 patients with refractory/relapsed disease, 4 are alive. Progression free survival at 18 months is 89%. Conclusions: Administration of R-CHOP-14 is feasible and early results show favorable efficacy. Most cycles can be delivered on time and at full dose except for VCR, which was dose-reduced in one third of cycles. Early results are encouraging and warrant comparison to R-CHOP-21. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ortho Biotech IDEC Ligand; Ortho Biotech; Schering-Plough Clinical Lymphoma Clinical Lymphoma